| the effect of progesterone in the prevention of preterm delivery | Comparison of the Effects of Vaginal Progesterone (Cyclogest) and Intramuscular Progesterone (Hydroxyprogesterone Caproate) in the Prevention of Preterm Labor | IRCT2015040921670N1 |
| Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa | Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate for Prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women With Placenta Previa: A Randomized Controlled Study | NCT03779451 |
| effect of progestron in preterm labor | Comparing the efficacy of vaginal progesterone (cyclogest) versus injection of 17a hydroxyprogesterone caproate ( proluton) in preventing of preterm brth less than 34 weeks gestation in pregnant women with threatend abortion in Arash Hospita | IRCT2014123120504N1 |
| Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth | Relationship Between Plasma Concentration of (Hydroxyprogesterone Caproate) 17-OHPC and Preterm Birth | NCT03292731 |
| Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate | | NCT00120640 |
| Intramuscular Hydroxyprogesterone Caproate and Placenta Previa | The Use Of Intramuscular Hydroxyprogesterone Caproate For Management Of Placenta Previa Before 34 Weeks Of Gestation | NCT03130504 |
| Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women | A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women | NCT02937766 |
| Effect of 17 a-Hydroxyprogesterone caproate on prevention of preterm labor. | A clinical trial to comparison the effectiveness of 17 a-Hydroxyprogesterone caproate with routine prenatal care on prevention of preterm labor in patients with a history of preterm labor. | IRCT20190309042978N2 |
| Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women | A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women | NCT02940522 |
| 17-OHPC in Pregnancy: IM vs SC Routes | A Comparison of Intramuscular and Subcutaneous Administration of 17-hydroxyprogesterone Caproate (17-OHPC) in Pregnancy | NCT04183452 |
| To see the effect of INj proluton if given before surgery in patients with high risk operable breast cancer.� | A Phase III Randomized Controlled study of Inj. Proluton (Hydroxyprogesterone caproate) as single dose preoperative therapy in patients with high risk operable breast cancer.� | CTRI/2014/10/005098 |
| Single Injection 17-hydroxyprogesterone caproate in Preterm labour: a randomised controlled trial | | ISRCTN22145023 |
| An assessment of effect of pre operative Proluton in patients with operable breast cancer | An assessment of the effect of preoperative hydroxyprogesterone on serial levels of circulating tumour cells and serum nucleic acids (DNA and chromatin) in patients undergoing surgery for operable breast cancer. | CTRI/2014/11/005229 |
| 17OHP-C Dosing Among Obese Pregnant Women | Impact of a Higher Dose on the Pharmacokinetics of 17-alpha Hydroxyprogesterone Caproate in Obese Women | NCT03433040 |
| Progesterone in Expectantly Managed Early-onset Preeclampsia | Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study | NCT04077853 |
| Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS) | A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS) | NCT00099164 |
| Effect of proluton and cyclogest on perinatal outcome | Comparing the efficacy of 17a hydroxyprogesterone caproate ( proluton) versus vaginal progesterone (cyclogest) on perinatal outcome in high risk patients who undergo cerclage | IRCT20181107041585N4 |
| Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood | A Multi-Center, Non-Randomized Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood of Women With a Singleton Pregnancy and a Previous Singleton Spontaneous Preterm Delivery | NCT01899846 |
| 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographic short cervix | 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographic short cervix in ARASH hospital during 2012-2013 years | IRCT2012082610664N1 |
| Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone | Use of 17a Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor During Current Pregnancy. Double Blind, Randomized, Controlled Trial. | NCT01317225 |
| Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) | 17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial | NCT01119963 |
| Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery | A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery | NCT01004029 |
| 17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor | | NCT00809939 |
| A Randomized Trial of Cerclage Versus 17 a-Hydroxyprogesterone Caproate for Treatment of a Short Cervix | Histologic Evaluation of the Cervix at Risk for Preterm Birth Trial:Medical Versus Surgical Therapy | NCT00694967 |
| RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix | A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix | NCT00439374 |
| 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies | 17-Alpha-Hydroxyprogesterone Caproate for Reduction of Neonatal Morbidity Due to Preterm Birth in Twin and Triplet Pregnancies - A Concurrent Randomized Double-blinded Clinical Trial | NCT00163020 |
| Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate | Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate | NCT00141908 |
| A randomized controlled trial study on the effectiveness of 17 alpha hydroxyprogesterone and micronised progesterone in preventing preterm labor of pregnant women with arrested premature labor. | A randomized controlled trial study on the effectiveness of 17 alpha hydroxyprogesterone and micronised progesterone in preventing preterm labor of pregnant women with arrested premature labor. | TCTR20210407003 |
| comparison of oral Dydrogesterone and 17a Hydroxyprogesterone Caproate in prevention of preterm birth in patients with preterm labor | comparison of oral Dydrogesterone and 17a Hydroxyprogesterone Caproate in prevention of preterm birth in patients with preterm labor | IRCT20181207041879N1 |
